Literature DB >> 8708657

Huntington's disease: a molecular genetic and CT comparison.

P Sharma1, L Savy, J Britton, R Taylor, A Howick, M Patton.   

Abstract

Huntington's disease is a progressive neurodegenerative disease in which the molecular abnormality has recently been described. Before the availability of this molecular marker diagnosis depended on clinical findings, supported in some instances by neuroimaging using CT or MRI. The imaging modalities may show atrophy of the heads of caudate nuclei in affected people. An attempt was made to validate these imaging findings using the molecular test as "gold standard." Retrospective analysis of cranial CT in 16 patients with Huntington's disease and 16 age and sex matched controls was performed. There was a highly significant difference in caudate head size (P < 0.00001) between patients with Huntington's disease and control subjects. However, the sensitivity of diagnosis based on radiological examination alone was only 87.5% in this study. Thus the sensitivity of CT is insufficient to justify its routine use in the investigation of suspected Huntington's disease, unless genetic tests are negative and other diagnoses need to be excluded.

Entities:  

Mesh:

Year:  1996        PMID: 8708657      PMCID: PMC1073808          DOI: 10.1136/jnnp.60.2.206

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  10 in total

1.  Bicaudate index in computerized tomography of Huntington disease and cerebral atrophy.

Authors:  A N Barr; W J Heinze; G D Dobben; G E Valvassori; O Sugar
Journal:  Neurology       Date:  1978-11       Impact factor: 9.910

2.  Computed tomography for Huntington's disease.

Authors:  C F Terrence; J F Delaney; M C Alberts
Journal:  Neuroradiology       Date:  1977-06-27       Impact factor: 2.804

3.  A comparison of neurological, metabolic, structural, and genetic evaluations in persons at risk for Huntington's disease.

Authors:  S T Grafton; J C Mazziotta; J J Pahl; P St George-Hyslop; J L Haines; J Gusella; J M Hoffman; L R Baxter; M E Phelps
Journal:  Ann Neurol       Date:  1990-11       Impact factor: 10.422

4.  SPECT, CT and MRI in a Turkish family with Huntington's disease.

Authors:  R P Bruyn; G Hageman; J A Geelen; F A van der Weel; A R Rozeboom; F Barkhof; P Scheltens
Journal:  Neuroradiology       Date:  1993       Impact factor: 2.804

5.  Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons.

Authors:  E H Aylward; J Brandt; A M Codori; R S Mangus; P E Barta; G J Harris
Journal:  Neurology       Date:  1994-05       Impact factor: 9.910

6.  Bicaudate diameter--the most specific and simple CT parameter in the diagnosis of Huntington's disease.

Authors:  T Stober; W Wussow; K Schimrigk
Journal:  Neuroradiology       Date:  1984       Impact factor: 2.804

7.  A new polymerase chain reaction (PCR) assay for the trinucleotide repeat that is unstable and expanded on Huntington's disease chromosomes.

Authors:  J P Warner; L H Barron; D J Brock
Journal:  Mol Cell Probes       Date:  1993-06       Impact factor: 2.365

8.  Is direct CT caudatometry superior to indirect parameters in confirming Huntington's disease?

Authors:  C Lang
Journal:  Neuroradiology       Date:  1985       Impact factor: 2.804

9.  Clinical-pathologic correlation in Huntington's disease: a neuropsychological and computed tomography study.

Authors:  K A Bamford; E D Caine; D K Kido; W M Plassche; I Shoulson
Journal:  Neurology       Date:  1989-06       Impact factor: 9.910

10.  PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline.

Authors:  A B Young; J B Penney; S Starosta-Rubinstein; D S Markel; S Berent; B Giordani; R Ehrenkaufer; D Jewett; R Hichwa
Journal:  Ann Neurol       Date:  1986-09       Impact factor: 10.422

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.